Ajinomoto logo

Ajinomoto

Last updated January 31, 2026
72
Innovation Areas
1,635
Inventors
14
Collaborations

Cleavable antibody functional substance conjugates: AjinomotoRecent Research Landscape

Uncontrolled attachment of payloads to antibodies leads to heterogeneous drug-to-antibody ratios and reduced therapeutic efficacy. These innovations utilize site-specific chemical handles to ensure precise molecular orientation and stoichiometric consistency.

What technical problems is Ajinomoto addressing in Cleavable antibody functional substance conjugates?

Insufficient targeted payload delivery

(16)evidences

Random conjugation leads to heterogeneous mixtures with unpredictable pharmacokinetics and reduced therapeutic efficacy. Achieving regioselectivity prevents inconsistent drug-to-antibody ratios and suboptimal binding affinity.